Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The co-occurrence of obesity with cancer-related fatigue and their impact on physical function among breast cancer survivors.

Cancer survivorship research & care·2026
Same author

The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent.

The American journal of cardiology·2025
Same author

The Efficacy of Nitric Oxide-Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patients of African American and Hispanic Origin.

The American journal of medicine·2023
Same author

Ancestral Stem Cell Reprogramming Genes Active in Hemichordate Regeneration.

Frontiers in ecology and evolution·2023
Same author

Infectious Bronchitis Hatchery Vaccination: Comparison between Traditional Spray Administration and a Newly Developed Gel Delivery System in Field Conditions.

Veterinary sciences·2021
Same author

A Study of Proton Pump Inhibitors and Other Risk Factors in Warfarin-Associated Gastrointestinal Bleeding.

Cureus·2021

Related Experiment Videos

Short and long-term mortality with nesiritide.

Rohit R Arora1, Prasanna Kumar Venkatesh, Janos Molnar

  • 1The Department of Medicine, The Chicago Medical School, Chicago, IL 60064, USA. rohit.arora@va.gov

American Heart Journal
|December 13, 2006
PubMed
Summary

This meta-analysis found no increased short-term or long-term mortality risk with nesiritide use in acute decompensated heart failure patients. Further research is needed to identify potential risk subgroups.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Nesiritide (recombinant human B-type natriuretic peptide) offers symptomatic and hemodynamic benefits in acute decompensated heart failure.
  • Previous meta-analysis suggested a potential increased short-term mortality risk with nesiritide.
  • This study re-evaluates nesiritide's mortality risk using a larger trial set.

Purpose of the Study:

  • To assess the short- and long-term mortality risk associated with nesiritide in acute decompensated heart failure.
  • To provide an updated meta-analysis of randomized controlled trials on nesiritide and mortality.

Main Methods:

  • Meta-analysis of 7 randomized controlled trials involving nesiritide for acute decompensated heart failure.
  • Inclusion of trials with available 30-day mortality data; 4 trials provided 180-day mortality data.
  • Extraction of mortality data from trial arms and the nesiritide database.

Main Results:

  • Pooled analysis showed no significant difference in unadjusted 30-day mortality between nesiritide and control groups (RR 1.243).
  • Pooled analysis indicated no significant difference in unadjusted 180-day mortality between nesiritide and control groups (RR 0.002).

Conclusions:

  • This meta-analysis suggests nesiritide is not associated with increased 30- or 180-day mortality.
  • Further investigation into confounding variables may identify patient subgroups at risk.
  • Large-scale trials are necessary to definitively confirm these findings on mortality.